Tumor Necrosis Factor Alpha -308 G/A Single Nucleotide Polymorphism and Susceptibility to Hepatocellular Carcinoma Via Hepatitis B Infection

Abstract

Background: Hepatitis B virus (HBV) is a key factor for hepatocellular carcinoma (HCC). About 350 million people are affected by chronic infection which is related to the rapid development of liver diseases as well as hepatitis, cirrhosis and hepatocellular carcinoma. Expression of tumor necrosis factor alpha (TNF-${\alpha}$) in the liver demonstrates a major genetic polymorphism which is involved in resistance or susceptibility to chronic HBV infection. Materials and Methods: In this study, two populations were studied by the sequence specific primer-polymerase chain reaction (SSP-PCR) method: HBV cases (n=409), who were HBS-Ag+, and healthy controls (n=483). Results: The results shown that the frequency of TNF-${\alpha}$ -308 G/G genotype in healthy controls (47.2%) was significantly higher than in HBV infected patients (28%) (CI = 1.29-2.61, OR = 1.83, P = 0.0004). Also TNF-${\alpha}$ -308 A/A and A/G genotype frequencies in the healthy controls were 4.6% and 48.2% and in patient group were 19.5% and 52.5% (CI = 2.23-7.12, p: 0.0001, OR: 3.94) respectively. Conclusions: We found that among Iranian people TNF-${\alpha}$ -308A allele not only has the highest genotype frequency but also it has the highest frequency in the world population. In addition, TNF-${\alpha}$-308 G/G polymorphism was associated with HBV resistance, whereas TNF-${\alpha}$-308A (A/A or A/G) polymorphism appeared to associated with chronic HBV infection. These data suggested that among the Iranian population, the -308 G/G polymorphism of TNF-${\alpha}$ gene promoter region has the potential to influence the susceptibility to HBV infection and it may be responsible for viral antigen clearance.

Keywords

• Gene susceptibility;
• hepatitis B virus;
• predisposing factor;
• tumor necrosis factor alpha

References

1. Ben-Ari Z, Mor E, Papo O, et al (2003). Cytokine gene polymorphisms in patients infected with hepatitis B virus. Am J Gastroenterol, 98, 144-50. https://doi.org/10.1111/j.1572-0241.2003.07179.x
2. Chanthra N, Payungporn S, Chuaypen N, et al (2015). Single Nucleotide Polymorphisms in STAT3 and STAT4 and risk of hepatocellular carcinoma in Thai patients with chronic hepatitis B. Asian Pac J Cancer Prev, 16, 8405-10.
3. Di Bisceglie AM (2009). Hepatitis B And Hepatocellular Carcinoma. Hepatol, 49, 56-60. https://doi.org/10.1002/hep.22962
4. Gao J, Xie L, Yang WS, et al (2012). Risk factors of hepatocellular carcinoma--current status and perspectives. Asian Pac J Cancer Prev, 13, 743-52. https://doi.org/10.7314/APJCP.2012.13.3.743
5. Hajiani E, Masjedizadeh R, Hashemi J, et al (2005). Risk factors for hepatocellular carcinoma in Southern Iran. Saudi Med J, 26, 974-7.
6. Jeng JE, Wu HF, Tsai MF, et al (2014). Independent and additive interaction between tumor necrosis factor beta +252 polymorphisms and chronic hepatitis B and C virus infection on risk and prognosis of hepatocellular carcinoma: a case-control study. Asian Pac J Cancer Prev, 15, 10209-15.
7. Kay A, Zoulim F (2007). Hepatitis B virus genetic variability and evolution. Virus Res, 127, 164-76. https://doi.org/10.1016/j.virusres.2007.02.021
8. Kim YJ, Lee HS, Yoon JH, et al (2003). Association of TNFalpha promoter polymorphisms with the clearance of hepatitis B virus infection. Hum Mol Genet, 12, 2541-6. https://doi.org/10.1093/hmg/ddg262
9. Kumar V, Abbas AK, Fausto N, et al (2014). Robbins and cotran pathologic basis of disease, Elsevier Health Sci, 27.
10. Kummee P, Tangkijvanich P, Poovorawan Y, et al (2007). Association of HLA-DRB1*13 and TNF-alpha gene polymorphisms with clearance of chronic hepatitis B infection and risk of hepatocellular carcinoma in Thai population. J Viral Hepat, 14, 841-8.
11. Li N, Gao YF, Zhang TC, et al (2012). Relationship between interleukin 18 polymorphisms and susceptibility to chronic hepatitis B virus infection. World J Hepatol, 4, 105-9. https://doi.org/10.4254/wjh.v4.i3.105
12. Limothai U, Wasitthankasem R, Poovorawan Y, et al (2015). Single nucleotide polymorphism of interferon lambda-4 gene is not associated with treatment response to pegylated interferon in Thai patients with chronic hepatitis B. Asian Pac J Cancer Prev, 16, 5515-9. https://doi.org/10.7314/APJCP.2015.16.13.5515
13. Locksley RM, Killeen N, Lenardo MJ (2001). The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell, 104, 487-501. https://doi.org/10.1016/S0092-8674(01)00237-9
14. Mansoori M, Golalipour M, Alizadeh S, et al (2015). Genetic variation in the ABCB1 gene may lead to mRNA level chabge: application to gastric cancer cases. Asian Pac J Cancer Prev, 16, 8467-71.
15. Merat S, Malekzadeh R, Rezvan H, et al (2000). Hepatitis B in Iran. Arch Iran Med, 3, 192-201.
16. Basturk B, Karasu Z, Kilic M, et al (2008). Association of TNF-alpha -308 polymorphism with the outcome of hepatitis B virus infection in Turkey. Infect Genet Evol, 8, 20-5. https://doi.org/10.1016/j.meegid.2007.09.001
17. Beck J, Nassal M (2007). Hepatitis B virus replication. World J Gastroenterol, 13, 48-64. https://doi.org/10.3748/wjg.v13.i1.48
18. Nun-Anan P, Chonprasertsuk S, Siramolpiwat S, et al (2015). CYP2C19 genotype could be a predictive factor for aggressive manifestations of hepatocellular carcinoma related with chronic hepatitis B infection in Thailand. Asian Pac J Cancer Prev, 16, 3253-6. https://doi.org/10.7314/APJCP.2015.16.8.3253
19. Pourhoseingholi MA, Fazeli Z, Zali MR, et al (2010). Burden of hepatocellular carcinoma in Iran; bayesian projection and trend analysis. Asian Pac J Cancer Prev, 11, 859-62.
20. Pungpapong S, Kim WR, Poterucha JJ (2007). Natural history of hepatitis B virus infection: an update for clinicians. Mayo Clin Proc, 82, 967-75. https://doi.org/10.4065/82.8.967
21. Seeger C, Mason WS (2000). Hepatitis B virus biology. Microbiol Mol Biol Rev, 64, 51-68. https://doi.org/10.1128/MMBR.64.1.51-68.2000
22. Shamszad M, Farzadegan H (1982). Hepatitis B related cirrhosis and hepatocellular carcinoma in Iran. J Irn Med Council, 8, 238.
23. Somi MH, Najafi L, Noori BN, et al (2006). Tumor necrosis factor-alpha gene promoter polymorphism in Iranian patients with chronic hepatitis B. Indian J Gastroenterol, 25, 14-5.
24. Tayebi S, Mohamadkhani A (2012). The TNF-alpha -308 promoter gene polymorphism and chronic HBV Infection. Hepat Res Treat, 2012, 493219.
25. Wang B, Wang J, Zheng Y, et al (2010). A study of TNF-alpha-238 and -308 polymorphisms with different outcomes of persistent hepatitis B virus infection in China. Pathol, 42, 674-80. https://doi.org/10.3109/00313025.2010.523696
26. Wang C, Tang J, Song W, et al (2004). HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination. Hepatol, 39, 978-88. https://doi.org/10.1002/hep.20142
27. Wang CH, Wey KC, Mo LR, et al (2015). Current trends and recent advances in diagnosis, therapy, and prevention of hepatocellular carcinoma. Asian Pac J Cancer Prev, 16, 3595-604. https://doi.org/10.7314/APJCP.2015.16.9.3595
28. Wirz SA, Morale MC, Marchetti B, et al (2004). High frequency of TNF alleles -238A and -376A in individuals from northern Sardinia. Cytokine, 26, 149-54. https://doi.org/10.1016/j.cyto.2004.02.006
29. Xu XW, Lu MH, Tan DM (2005). Association between tumour necrosis factor gene polymorphisms and the clinical types of patients with chronic hepatitis B virus infection. Clin Microbiol Infect, 11, 52-6. https://doi.org/10.1111/j.1469-0691.2004.01029.x
30. Zheng MH, Qiu LX, Xin YN, et al (2010). Tumor necrosis factoralpha- 308A allele may have a protective effect for chronic hepatitis B virus infection in Mongoloid populations. Int J Infect Dis, 14, 580-5. https://doi.org/10.1016/j.ijid.2009.08.010
31. Zuckerman AJ (1996). Hepatitis viruses. in 'medical microbiology', eds university of texas medical branch at galveston. The University of Texas Medical Branch at Galveston, Galveston (TX).